BR112021022194A2 - Formulações líquidas para dosagem oral de metilnaltrexona - Google Patents

Formulações líquidas para dosagem oral de metilnaltrexona

Info

Publication number
BR112021022194A2
BR112021022194A2 BR112021022194A BR112021022194A BR112021022194A2 BR 112021022194 A2 BR112021022194 A2 BR 112021022194A2 BR 112021022194 A BR112021022194 A BR 112021022194A BR 112021022194 A BR112021022194 A BR 112021022194A BR 112021022194 A2 BR112021022194 A2 BR 112021022194A2
Authority
BR
Brazil
Prior art keywords
methylnaltrexone
liquid formulations
oral dosing
docusate
surfactant
Prior art date
Application number
BR112021022194A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Rohrs Brian
Jason Stein Daniel
Eric Phillips
Vijay Kumar
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Publication of BR112021022194A2 publication Critical patent/BR112021022194A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021022194A 2019-05-07 2020-05-07 Formulações líquidas para dosagem oral de metilnaltrexona BR112021022194A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962844613P 2019-05-07 2019-05-07
US202063010528P 2020-04-15 2020-04-15
PCT/EP2020/062794 WO2020225395A1 (en) 2019-05-07 2020-05-07 Liquid oral dosage formulations of methylnaltrexone

Publications (1)

Publication Number Publication Date
BR112021022194A2 true BR112021022194A2 (pt) 2021-12-28

Family

ID=70802839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022194A BR112021022194A2 (pt) 2019-05-07 2020-05-07 Formulações líquidas para dosagem oral de metilnaltrexona

Country Status (9)

Country Link
US (1) US20220096461A1 (enExample)
EP (1) EP3965731A1 (enExample)
JP (1) JP7692366B2 (enExample)
CN (1) CN113747882A (enExample)
AU (1) AU2020268767B8 (enExample)
BR (1) BR112021022194A2 (enExample)
CA (1) CA3137488C (enExample)
MX (1) MX2021013488A (enExample)
WO (1) WO2020225395A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
AU2022248850A1 (en) * 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
WO2025177181A1 (en) * 2024-02-19 2025-08-28 Nanoprime Labs Corp Self-assembling microemulsions carrying nutraceuticals and methods for use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4816259A (en) 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN1688294A (zh) 2002-10-01 2005-10-26 旗帜药物胶囊公司 用于制备软胶囊壁的肠溶组合物
MXPA05010821A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI605814B (zh) * 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
JP6397813B2 (ja) 2012-05-02 2018-09-26 キャプシュゲル・ベルジウム・エヌ・ヴィ ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液
US10485798B2 (en) * 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
EP3206491B1 (en) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Also Published As

Publication number Publication date
AU2020268767B1 (en) 2025-07-17
CA3137488C (en) 2023-10-31
CN113747882A (zh) 2021-12-03
WO2020225395A1 (en) 2020-11-12
JP7692366B2 (ja) 2025-06-13
AU2020268767A1 (en) 2021-10-28
MX2021013488A (es) 2021-12-10
AU2020268767B8 (en) 2025-08-07
JP2022531685A (ja) 2022-07-08
EP3965731A1 (en) 2022-03-16
CA3137488A1 (en) 2020-11-12
US20220096461A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
PH12017501774A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2017009482A (es) Formulación farmacéutica.
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112018003984A2 (pt) anticorpos
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
MX2021013488A (es) Formulaciones liquidas de dosis oral de metilnaltrexona.
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
MX2023002482A (es) Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
MX2017016774A (es) Agente terapeutico para la fibrosis.
BR112023006143A2 (pt) Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
BR112019001207A2 (pt) composição vaginal compreendendo uma combinação de estrogênio e vitamina d
BR112015027112A2 (pt) uso de uma mistura, e, formulação de ingrediente ativo aquoso
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
BR112021014911A2 (pt) Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]